Jesús
San Miguel Izquierdo
Consultor Investigador
University Hospital of Zurich
Zúrich, SuizaPublicacións en colaboración con investigadores/as de University Hospital of Zurich (3)
2019
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 253-264
2015
-
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Haematologica, Vol. 100, Núm. 10, pp. 1327-1333
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Haematologica, Vol. 100, Núm. 10, pp. 1334-1339